申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP0921125A1
公开(公告)日:1999-06-09
The present invention relates to compounds of the general formula
wherein
R1is hydrogen, lower alkyl, halogen, lower alkoxy, trifluoromethyl, lower alkyl-phenyl or (C5-7)-cycloalkyl;
R2is hydrogen, lower alkyl, phenyl or lower alkyl-phenyl;
R3is hydrogen, lower alkyl, benzyl, lower alkyl-phenyl, lower alkyl-diphenyl, triazinyl, cyanomethyl, lower alkyl-piperidinyl, lower alkyl-naphthyl, (C5-7)-cycloalkyl, lower alkyl-(C5-7)-cycloalkyl, lower alkyl-pyridinyl, lower alkyl-morpholinyl, lower alkyl-dioxolanyl, lower alkyl-oxazolyl or lower alkyl-2-oxo-oxazolidinyl and wherein the ring systems may be substituted by additional lower alkyl, lower alkoxy, trifluoromethyl or phenyl, or -(CH2)nC(O)O-lower alkyl, -(CH2)nC(O)NH2, -(CH2)nC(O)N(lower alkyl)2, -(CH2)nOH or -(CH2)nC(O)NHCH2C6H5;
R4is hydrogen, lower alkyl or nitrilo;
Ais a ring system, consisting of
(a) (C5-15)-cycloalkyl, which may be in addition to R4optionally substituted by lower alkyl, trifluoromethyl, phenyl, (C5-7)-cycloalkyl, spiro-undecan-alkyl or by 2-norbornyl, or is one of the following groups
dodecahydro-acenaphthylen-1yl (e), bicyclo[6.2.0]dec-9-yl (f) and bicyclononan-9-yl (g);
and wherein
R5 and R6are hydrogen, lower alkyl or taken together and with the carbon atoms to which they are attached form a phenyl ring;
R7is hydrogen or lower alkyl;
the dotted line represents an optional bond and
nis 1 to 4;
and to pharmaceutically acceptable acid addition salts thereof.
Compounds of the present invention are agonists and/or antagonists of the Orphanin FQ (OFQ) receptor. Consequently they will be useful in the treatment of memory and attention deficits, psychiatric, neurological and physiological disorders, especially, but not limited to, amelioration of symptoms of anxiety and stress disorders, depression, trauma, memory loss due to Alzheimer's disease or other dementias, epilepsy and convulsions, acute and/or chronic pain conditions, symptoms of addictive drug withdrawal, control of water balance, Na+ excretion, arterial blood pressure disorders and metabolic disorders such as obesity.
本发明涉及通式如下的化合物
式中
R1是氢、低级烷基、卤素、低级烷氧基、三氟甲基、低级烷基苯基或(C5-7)-环烷基;
R2 是氢、低级烷基、苯基或低级烷基苯基;
R3是氢、低级烷基、苄基、低级烷基-苯基、低级烷基-二苯基、三嗪基、氰甲基、低级烷基-哌啶基、低级烷基-萘基、(C5-7)-环烷基、低级烷基-(C5-7)-环烷基、低级烷基-吡啶基、低级烷基-吗啉基、低级烷基-二氧戊环基、低级烷基-噁唑基或低级烷基-2-氧代-噁唑烷基,其中环系统可被额外的低级烷基、低级烷氧基、三氟甲基或苯基取代,或被-(CH2)nC(O)O-低级烷基、-(CH2)nC(O)NH2、-(CH2)nC(O)N(低级烷基)2、-(CH2)nOH 或 -(CH2)nC(O)NHCH2C6H5取代;
R4 是氢、低级烷基或硝基;
A 是一个环状系统,包括
(a) (C5-15)-环烷基,除 R4 外,还可被低级烷基、三氟甲基、苯基、(C5-7)-环 烷基、螺十一烷基或 2-降冰片基取代,或为以下基团之一
十二氢-苊烯-1-基 (e)、双环[6.2.0]癸-9-基 (f) 和双环壬-9-基 (g);
其中
R5 和 R6 为氢、低级烷基或与它们所连接的碳原子一起形成苯环;
R7 为氢或低级烷基;
虚线代表任选键,且
n为 1 至 4;
及其药学上可接受的酸加成盐。
本发明的化合物是孤儿素 FQ(OFQ)受体的激动剂和/或拮抗剂。因此,它们可用于治疗记忆和注意力缺陷、精神、神经和生理疾病,特别是但不限于改善焦虑和应激障碍、抑郁症、创伤、阿尔茨海默病或其他痴呆症引起的记忆丧失、癫痫和抽搐、急性和/或慢性疼痛、成瘾药物戒断症状、控制水平衡、Na+排泄、动脉血压紊乱和代谢紊乱(如肥胖)等症状。